Actinium Pharmaceuticals (STU:7AY1) EV-to-Revenue : 1,939.23 (As of Jun. 05, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Actinium Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Actinium Pharmaceuticals's enterprise value is €143.50 Mil. Actinium Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.07 Mil. Therefore, Actinium Pharmaceuticals's EV-to-Revenue for today is 1,939.23.

The historical rank and industry rank for Actinium Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

STU:7AY1' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.95 Med: 128.81 Max: 2360.59
Current: 1922.66

During the past 13 years, the highest EV-to-Revenue of Actinium Pharmaceuticals was 2360.59. The lowest was 0.95. And the median was 128.81.

STU:7AY1's EV-to-Revenue is ranked worse than
97.01% of 1038 companies
in the Biotechnology industry
Industry Median: 7.985 vs STU:7AY1: 1922.66

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-05), Actinium Pharmaceuticals's stock price is €7.305. Actinium Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Therefore, Actinium Pharmaceuticals's PS Ratio for today is 2,435.00.

Actinium Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Actinium Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals EV-to-Revenue Chart

Actinium Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

48.57

162.24

812.56

Actinium Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															1,678.68	2,473.01	-	812.56	1,828.38

Competitive Comparison of Actinium Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Actinium Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actinium Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's EV-to-Revenue falls into.

Actinium Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Actinium Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	143.503	/	0.074
	=	1,939.23

Actinium Pharmaceuticals's current Enterprise Value is €143.50 Mil.
Actinium Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.07 Mil.

Actinium Pharmaceuticals (STU:7AY1) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Actinium Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	7.305	/	0.003
	=	2,435.00

Actinium Pharmaceuticals's share price for today is €7.305.
Actinium Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

Actinium Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinium Pharmaceuticals (STU:7AY1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (STU:7AY1) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

ATNM:USA 7AY1:Germany

Address

275 Madison Avenue, 7th Floor, New York, NY, USA, 10016

Website

https://www.actiniumpharma.com

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals (STU:7AY1) Headlines

No Headlines